Takeda announces FDA approval for EXKIVITY™ (mobocertinib)
Takeda has announced that the US Food and Drug Administration (FDA) has approved EXKIVITY™ (mobocertinib), the first oral therapy to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations in metastatic non-small cell lung cancer (NSCLC).1 EXKIVITY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic NSCLC […]